Mont-Saint-Guibert, Belgium (October 30, 2023) –
Cellistic is pleased to announce the appointment of Jonas Mortensen as Chief Commercial Officer from November 6, 2023.
Jonas will come from a position with Almac as VP business development and marketing and has over 15 years of experience in leading Global Business Development & Marketing teams in Almac and before that regionally teams and global accounts in Thermo Fisher and Patheon. Prior to that Jonas has worked as a Quality manager in a Danish pharma company, within project management and R&D with a background in Biology.
Jonas will report into Gustavo Mahler, Chief Executive Officer, and will be a member of the Executive Team as well as the Cellistic Leadership Team.
Jonas Mortensen, Cellistic CCO about his new role: “It is very exciting to join Cellistic and get closer to the biology again. Upon doing my own due diligence before joining, it became very clear to me that there is a need for an iPSC platform that enables cell therapies to get to clinic faster and with an economic model that provides better market and patient access. I look forward in supporting Cellistic and their Partners in this endeavor.”
Launched in April 2022, Cellistic™ specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. Its focus and expertise in iPSC reprogramming, differentiation, and expansion protocol development positions the business to be the partner of choice for innovative cell therapy developers to commercialize novel advanced therapies. Leveraging more than a decade of Ncardia’s scientific and technical knowledge and experience, Cellistic possesses unique capabilities for the design and optimization of proprietary manufacturing platforms for iPSC- based cells that deliver quality products at scale.